EZH2 and cancer: EZH2 is the catalyst subunit of PRC2 and mutation will be happened in several cancers, such as DLBCL.259EPZ6438 is a selective EZH2 inhibitor approved for epithelioid sarcoma.260 In fact, EZH2 also mediates transcriptional activation independent of EZH2/PRC2 catalytic activity in some cancers.